Instructions for use of Atrasentan in patients with IgA nephropathy

In April 20254, the United StatesFDA officially accelerated the approval of atrasentan (English name: Atr asentan, brand name: Vanrafia), is indicated for the treatment of adult patients with primary IgA nephropathy who are at increased risk for proteinuria. This marks atrasentan as the first endothelin A receptor antagonist approved specifically to reduce proteinuria in this patient population. The drug is developed and produced by Novartis, a world-renowned pharmaceutical company (Novartis). It has a clear target mechanism and good treatment prospects.

Atrasentan is an oral tablet. The dosage of each tablet is 0.75mg. It is recommended to be taken once a day. It does not depend on the meal time and can be taken with a meal or on an empty stomach. Patients should swallow the tablet whole and do not crush, chew or break it. VanrafiaMainly applicable to urine protein/creatinine ratio (UPCR) ≥1.5g/g, and the disease develops rapidly in patients with IgA kidney disease to control proteinuria levels.

In terms of pharmacological effects, atrasentan, as a selective ETA (endothelinA) receptor antagonist, can have It effectively blocks the signaling pathway mediated by ETA receptors, thereby reducing the inflammatory and fibrotic reactions triggered by endothelin-1 in glomeruli. Studies have shown that the drug's affinity for ETA receptors is significantly stronger than ETB receptors, helping to more accurately control the progression of IgA nephropathy.

Although atrasentan provides a new option for patients, the risk of pregnancy must be ruled out before use. The drug is contraindicated in pregnant women because animal experiments have shown that it has fetal toxicity. In addition, patients with a history of allergy to atrasentan or its excipients (such as lactose, povidone, silicon dioxide, etc.) should also avoid use.

During use, the most common adverse reactions include peripheral edema and mild anemia. Since this drug may affect liver function, it is recommended to regularly test liver function before and during treatment. If there is a significant increase in transaminases or related symptoms, such as jaundice, loss of appetite, nausea, dark urine, etc., the doctor should be informed in time and consider adjusting or suspending the medication.

At the same time, attention should be paid to drug interactions with atrasentan. When using it, avoid combining it with strong or moderate CYP3A inducers to avoid lowering blood concentrations. In addition, it is also necessary to avoid taking OATP1B1/1B3 inhibitors at the same time, because these drugs will significantly increase the risk of exposure of atrasentan in the body and may cause adverse cardiovascular events.

In special groups, lactating women are not recommended to take this drug because there is currently no clear data on whether it will enter breast milk. For elderly patients aged 65 years and above, clinical studies have not shown that the safety and efficacy are significantly different from those of younger patients. However, the safety and effectiveness of atrasentan in pediatric patients have not been determined, so it is not recommended for pediatric use.

Overall, atrasentan provides a new treatment option with a targeted mechanism for people at high risk of IgA kidney disease. The drug inhibits inflammatory and fibrotic pathways by antagonizing ETA receptors, helping to control proteinuria and delay disease progression. During clinical use, attention should be paid to pregnancy risks, liver function monitoring and drug interactions to ensure safe medication use.

Reference materials:https://www.novartis.com/us-en/sites/novartis_us/files/vanrafia.pdf